搜索替代詞:
harm » farm (擴展搜索)
resolve. » resolved. (擴展搜索)
resolves. » resolveds. (擴展搜索), resolved. (擴展搜索)
evolved. » resolved. (擴展搜索)
Showing 1 - 20 results of 175 for search 'harm is ((resolve. OR (evolved. OR (resolves. OR involves.))) OR involved.)', 查詢時間: 0.12s Refine Results
  1. 1
    Surface Hopping Molecular Dynamics Simulations for Photochemistry Involving Pyrene and CH<sub>3</sub>Cl

    Surface Hopping Molecular Dynamics Simulations for Photochemistry Involving Pyrene and CH<sub>3</sub>Cl 由 Elham Mazarei (4508746)

    出版 2025
    主題:
    加到收藏夾
    Saved in:
  2. 2
    Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings.

    Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings. 由 Diana M. Hendrickx (1507435)

    出版 2025
    加到收藏夾
    Saved in:
  3. 3
    Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings when using the persistent CMA group as a reference.

    Development of immune factors over visits in the persistent and resolved CMA group as (A) scores and (B) loadings when using the persistent CMA group as a reference. 由 Diana M. Hendrickx (1507435)

    出版 2025
    加到收藏夾
    Saved in:
  4. 4
    Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings.

    Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings. 由 Diana M. Hendrickx (1507435)

    出版 2025
    加到收藏夾
    Saved in:
  5. 5
    Results of comparing visits within allergy groups using linear mixed models and post hoc analysis.

    Results of comparing visits within allergy groups using linear mixed models and post hoc analysis. 由 Diana M. Hendrickx (1507435)

    出版 2025
    加到收藏夾
    Saved in:
  6. 6
    Results of comparing allergy groups within visits using linear mixed models and post hoc analysis.

    Results of comparing allergy groups within visits using linear mixed models and post hoc analysis. 由 Diana M. Hendrickx (1507435)

    出版 2025
    加到收藏夾
    Saved in:
  7. 7
    Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference.

    Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference. 由 Diana M. Hendrickx (1507435)

    出版 2025
    加到收藏夾
    Saved in:
  8. 8
    Results of comparing treatment groups within visits using linear mixed models and post hoc analysis.

    Results of comparing treatment groups within visits using linear mixed models and post hoc analysis. 由 Diana M. Hendrickx (1507435)

    出版 2025
    加到收藏夾
    Saved in:
  9. 9
    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis.

    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis. 由 Diana M. Hendrickx (1507435)

    出版 2025
    加到收藏夾
    Saved in:
  10. 10
    Results of comparing visits within treatment groups using linear mixed models and post hoc analysis.

    Results of comparing visits within treatment groups using linear mixed models and post hoc analysis. 由 Diana M. Hendrickx (1507435)

    出版 2025
    加到收藏夾
    Saved in:
  11. 11
    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis.

    Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis. 由 Diana M. Hendrickx (1507435)

    出版 2025
    加到收藏夾
    Saved in:
  12. 12
    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determined with ConsensusPathDB.

    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determ... 由 Diana M. Hendrickx (1507435)

    出版 2025
    加到收藏夾
    Saved in:
  13. 13
    Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB. 由 Diana M. Hendrickx (1507435)

    出版 2025
    加到收藏夾
    Saved in:
  14. 14
    Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB. 由 Diana M. Hendrickx (1507435)

    出版 2025
    加到收藏夾
    Saved in:
  15. 15
    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within treatment groups as determined with ConsensusPathDB.

    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within treatment groups as determ... 由 Diana M. Hendrickx (1507435)

    出版 2025
    加到收藏夾
    Saved in:
  16. 16
    Results of comparing visits within treatment groups using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing visits within treatment groups using KEGG pathway enrichment in ConsensusPathDB. 由 Diana M. Hendrickx (1507435)

    出版 2025
    加到收藏夾
    Saved in:
  17. 17
    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within allergy groups as determined with ConsensusPathDB.

    KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within allergy groups as determin... 由 Diana M. Hendrickx (1507435)

    出版 2025
    加到收藏夾
    Saved in:
  18. 18
    Results of comparing visits within allergy groups using KEGG pathway enrichment in ConsensusPathDB.

    Results of comparing visits within allergy groups using KEGG pathway enrichment in ConsensusPathDB. 由 Diana M. Hendrickx (1507435)

    出版 2025
    加到收藏夾
    Saved in:
  19. 19
    Potential mechanisms for persistent CMA (left) and resolution of CMA (right) revealed by our study.

    Potential mechanisms for persistent CMA (left) and resolution of CMA (right) revealed by our study. 由 Diana M. Hendrickx (1507435)

    出版 2025
    加到收藏夾
    Saved in:
  20. 20
    Participants’ perceptions of the likelihood of being harmed when receiving hospital or ambulatory care from 2019 to 2023 (N = 1000 per year).

    Participants’ perceptions of the likelihood of being harmed when receiving hospital or ambulatory care from 2019 to 2023 (N = 1000 per year). 由 Olga Amberger (20299807)

    出版 2025
    加到收藏夾
    Saved in:

檢索工具: